Formulation Development
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
Vaccinex, Inc. recently announced it has completed enrollment goal in the SIGNAL-AD clinical trial for people with mild dementia due to Alzheimer’s Disease (NCT04381468). Topline…
Radiant Biotherapeutics Emerges From Stealth Mode With $8-Million Seed Round & Two Pharma Partnerships
Radiant Biotherapeutics emerged from stealth mode unveiling an $8-million seed financing and two significant pharmaceutical partnerships. The company, based on foundational IP from….
Artelo Biosciences Initiates Phase 2a Portion of its CAReS Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia & Weight Loss
Artelo Biosciences, Inc. recently announced it has initiated the Phase 2a portion of its Cancer Appetite Recovery Study (CAReS), evaluating ART27.13 for the treatment of cancer-related anorexia…
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
Avidity Biosciences, Inc. recently announced the US FDA has granted Fast Track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) in…
Medigene AG Presents Final Phase 1 Data of TCR-T Cell Therapy in Patients With High-Risk Blood Cancers
Medigene AG recently reported final Phase 1 dose escalation results from first-in-human Study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy (MDG1011)…
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia
NewAmsterdam Pharma Company N.V. announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia….
Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection With Transition Into Commercial-Stage Biotechnology Company
Blue Water Vaccines Inc. recently announced it has changed its corporate name to Blue Water Biotech, Inc. The corporate name change follows the company’s recent…
Aevitas Therapeutics Announces Asset Purchase Agreement With 4D Molecular Therapeutics
Aevitas Therapeutics, Inc. and 4D Molecular Therapeutics recently announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its…
Merck Strengthens Immunology Pipeline With Acquisition of Prometheus Biosciences
Merck and Prometheus Biosciences, Inc. recently announced the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for….
Clearmind Medicine Engages Experienced CRO to Support its First-in-Human Clinical Trial
Clearmind Medicine Inc. recently announced additional preparations to facilitate the commencement of the company’s clinical trial and engaged a contract research organization (CRO) to provide support for….
United States Patent & Trademark Office Grants Evoke Pharma a Formulation Patent Covering GIMOTI
Evoke Pharma, Inc. recently announced the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title Nasal Formulations of Metoclopramide.…
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform & Advancements With its In Vivo Fusogen Platform
Sana Biotechnology, Inc. recently announced data from four presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting. “Sana remains focused on improving…
Roquette Cuts Ribbon on $25-Million Pharmaceutical Innovation Center in the US
Roquette recently celebrated the grand opening of its new Pharmaceutical Innovation Center, located near Philadelphia, PA, right in the heart of the United States’ Northeastern pharmaceutical corridor…..
Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology
Indaptus Therapeutics, Inc. recently announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the company’s Decoy…
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial for Aging-Related Frailty in Japan
Longeveron Inc. recently announced the first patient has been treated with Lomecel-B in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan.…
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety & PTSD Stress-Related Disorders
Silo Pharma, Inc. recently announced it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety,…
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
Ajinomoto Bio-Pharma Services recently announce the US FDA has approved the company’s high potency vial line to manufacture a commercial product…..
Quotient Sciences Supports Crinetics Pharmaceuticals With Fully Integrated Pediatric Development & Clinical Testing Program
Crinetics Pharmaceuticals and Quotient Sciences have recently announced a partnership to support Crinetics’ CRN04894 pediatric program. The partnership will utilize Quotient Sciences’ unique Translational Pharmaceutics…
PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne & San Diego
New equipment added to San Diego and Melbourne facilities will help with clinical scale and global capacity shortages….
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
Tiziana Life Sciences Ltd. recently announced it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 diabetes…..
